13.26
price up icon1.77%   0.23
after-market アフターアワーズ: 13.25 -0.010 -0.08%
loading

Cidara Therapeutics Inc (CDTX) 最新ニュース

pulisher
Oct 31, 2024

Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews

Oct 31, 2024
pulisher
Oct 31, 2024

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire

Oct 31, 2024
pulisher
Oct 30, 2024

How Cidara Got Its Molecule Back - BioProcess Online

Oct 30, 2024
pulisher
Oct 29, 2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat

Oct 29, 2024
pulisher
Oct 23, 2024

Cidara Therapeutics (NASDAQ:CDTX) Receives “Buy” Rating from HC Wainwright - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

Cidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat

Oct 22, 2024
pulisher
Oct 16, 2024

Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

(CDTX) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 14, 2024

Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 14, 2024
pulisher
Oct 14, 2024

Invasive Fungal Infection Market 2034 | Key Brands -Cidara Therapeutics, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 05, 2024

(CDTX) On The My Stocks Page - Stock Traders Daily

Oct 05, 2024
pulisher
Oct 04, 2024

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Oct 04, 2024
pulisher
Oct 02, 2024

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Oct 02, 2024
pulisher
Oct 02, 2024

Shattuck Labs stock craters following pipeline and job cuts - Pharmaceutical Technology

Oct 02, 2024
pulisher
Sep 25, 2024

Cidara Therapeutics Announces Two Presentations on - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

How to Take Advantage of moves in (CDTX) - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Long-acting Antiviral for Pre-exposure Protection Against Influenza Launches Phase 2b Study - Precision Vaccinations

Sep 24, 2024
pulisher
Sep 24, 2024

Cidara Therapeutics begins phase 2b trial for flu prophylaxis By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 24, 2024

Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Cidara starts Phase 2b trial of influenza drug CD388 By Investing.com - Investing.com Canada

Sep 23, 2024
pulisher
Sep 23, 2024

Codexis, Inc. (NASDAQ:CDXS) Major Shareholder Opaleye Management Inc. Purchases 45,000 Shares - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics begins phase 2b trial for flu prophylaxis - Investing.com India

Sep 23, 2024
pulisher
Sep 23, 2024

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara starts Phase 2b trial of influenza drug CD388 - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics Announces First Subjects Dosed in Phase - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - StockTitan

Sep 23, 2024
pulisher
Sep 20, 2024

Biotechs investigate ways to adapt to new clinical trial regulation and economic flux - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Cidara Therapeutics expands Scientific Advisory Board By Investing.com - Investing.com Canada

Sep 20, 2024
pulisher
Sep 19, 2024

Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

XTX Topco Ltd Purchases Shares of 8,284 Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Cidara Therapeutics expands Scientific Advisory Board - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts - GlobeNewswire

Sep 19, 2024
pulisher
Sep 19, 2024

Acute Vulvovaginal Candidiasis Treatment Market Size, Share, Growth and Industry Trends - meramandsaur.in

Sep 19, 2024
pulisher
Sep 18, 2024

Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches - Fierce Biotech

Sep 18, 2024
pulisher
Sep 18, 2024

IDWeek 2022 PresentationsIVVD, SPRO, INVA, CDTX, ANTX, GSK - RTTNews

Sep 18, 2024
pulisher
Sep 17, 2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Decrease in Short Interest - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Codexis Inc. (CDXS) Stock: A Year of Declines and Increases - The InvestChronicle

Sep 17, 2024
pulisher
Sep 17, 2024

The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Capricor Therapeutics Shares Rise After Deramiocel Deal With Nippon Shinyaku - MarketWatch

Sep 17, 2024
pulisher
Sep 16, 2024

Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

HC Wainwright Reaffirms "Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX) - MarketBeat

Sep 16, 2024
pulisher
Sep 15, 2024

Cognizant Technology Solutions (NASDAQ:CTSH) Stock Rating Upgraded by StockNews.com - Defense World

Sep 15, 2024
pulisher
Sep 14, 2024

Cidara therapeutics chief scientific officer sells shares worth over $10k - Investing.com India

Sep 14, 2024
pulisher
Sep 13, 2024

Cidara Therapeutics (NASDAQ:CDTX) Upgraded to "Hold" at StockNews.com - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells $10,755.36 in Stock - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

Cidara Therapeutics executive sells over $10k in company stock - Investing.com

Sep 13, 2024
pulisher
Sep 13, 2024

(CDTX) Trading Advice - Stock Traders Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Cidara Therapeutics announces workforce cut to focus on flu drug - Investing.com India

Sep 13, 2024
pulisher
Sep 13, 2024

Cidara Therapeutics announces workforce cut to focus on flu drug By Investing.com - Investing.com Australia

Sep 13, 2024
pulisher
Sep 13, 2024

Cidara axes 30% of staff to focus on flu prevention drug - Pharmaceutical Technology

Sep 13, 2024
pulisher
Sep 13, 2024

Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle

Sep 13, 2024
pulisher
Sep 12, 2024

Cidara Therapeutics announces workforce reduction and trial focus By Investing.com - Investing.com Canada

Sep 12, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):